Association between immune-related adverse events and recurrence dynamics under adjuvant anti–PD-1 therapy in resected melanoma
Cutaneous irAEs within 6 months of initiating adjuvant PD-1 blockade are independently associated with reduced recurrence risk and prolonged RFS. Early emergence of these events may serve as a dynamic marker of effective anti-tumor immunity in patients with resected high-risk melanoma.
Authors
- Haydar Çağatay Yüksel (ORCID: https://orcid.org/0000-0001-8857-2983)
- Banu Yaman (ORCID: https://orcid.org/0000-0002-2915-0788)
- Burçak Karaca (ORCID: https://orcid.org/0000-0003-2638-1625)
- Caner Acar (ORCID: https://orcid.org/0000-0002-9782-6807)
- Salih Tünbekici (ORCID: https://orcid.org/0000-0001-8804-7636)
- Gökhan Şahin (ORCID: https://orcid.org/0000-0003-3980-8034)
- Fatma Pınar Açar (ORCID: https://orcid.org/0009-0000-2749-8732)
Institutions
- Ege University (TR)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-11-07
- DOI
- https://doi.org/10.3389/fonc.2025.1671315
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00